58 related articles for article (PubMed ID: 38617799)
21. Selenium-Modified Chitosan Induces HepG2 Cell Apoptosis and Differential Protein Analysis.
Sun SJ; Deng P; Peng CE; Ji HY; Mao LF; Peng LZ
Cancer Manag Res; 2022; 14():3335-3345. PubMed ID: 36465707
[TBL] [Abstract][Full Text] [Related]
22. Bioavailability Enhancement Techniques for Poorly Aqueous Soluble Drugs and Therapeutics.
Bhalani DV; Nutan B; Kumar A; Singh Chandel AK
Biomedicines; 2022 Aug; 10(9):. PubMed ID: 36140156
[TBL] [Abstract][Full Text] [Related]
23. Boosting the Anticancer Activity of Sunitinib Malate in Breast Cancer through Lipid Polymer Hybrid Nanoparticles Approach.
Ahmed MM; Anwer MK; Fatima F; Aldawsari MF; Alalaiwe A; Alali AS; Alharthi AI; Kalam MA
Polymers (Basel); 2022 Jun; 14(12):. PubMed ID: 35746034
[TBL] [Abstract][Full Text] [Related]
24. Development and Evaluation of Chitosan Nanoparticles for Ocular Delivery of Tedizolid Phosphate.
Kalam MA; Iqbal M; Alshememry A; Alkholief M; Alshamsan A
Molecules; 2022 Apr; 27(7):. PubMed ID: 35408724
[TBL] [Abstract][Full Text] [Related]
25. FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation.
Casak SJ; Pradhan S; Fashoyin-Aje LA; Ren Y; Shen YL; Xu Y; Chow ECY; Xiong Y; Zirklelbach JF; Liu J; Charlab R; Pierce WF; Fesenko N; Beaver JA; Pazdur R; Kluetz PG; Lemery SJ
Clin Cancer Res; 2022 Jul; 28(13):2733-2737. PubMed ID: 35259259
[TBL] [Abstract][Full Text] [Related]
26. Chitosan-Coated-PLGA Nanoparticles Enhance the Antitumor and Antimigration Activity of Stattic - A STAT3 Dimerization Blocker.
Fong SS; Foo YY; Saw WS; Leo BF; Teo YY; Chung I; Goh BT; Misran M; Imae T; Chang CC; Chung LY; Kiew LV
Int J Nanomedicine; 2022; 17():137-150. PubMed ID: 35046650
[TBL] [Abstract][Full Text] [Related]
27. Development and Evaluation of Repurposed Etoricoxib Loaded Nanoemulsion for Improving Anticancer Activities against Lung Cancer Cells.
Md S; Alhakamy NA; Alharbi WS; Ahmad J; Shaik RA; Ibrahim IM; Ali J
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948081
[TBL] [Abstract][Full Text] [Related]
28. Advances in Chitosan-Based Nanoparticles for Drug Delivery.
Mikušová V; Mikuš P
Int J Mol Sci; 2021 Sep; 22(17):. PubMed ID: 34502560
[TBL] [Abstract][Full Text] [Related]
29. Gefitinib loaded PLGA and chitosan coated PLGA nanoparticles with magnified cytotoxicity against A549 lung cancer cell lines.
Alshetaili AS
Saudi J Biol Sci; 2021 Sep; 28(9):5065-5073. PubMed ID: 34466084
[TBL] [Abstract][Full Text] [Related]
30. Treatment for liver cancer: From sorafenib to natural products.
Man S; Luo C; Yan M; Zhao G; Ma L; Gao W
Eur J Med Chem; 2021 Nov; 224():113690. PubMed ID: 34256124
[TBL] [Abstract][Full Text] [Related]
31. Biomedical application of chitosan-based nanoscale delivery systems: Potential usefulness in siRNA delivery for cancer therapy.
Ashrafizadeh M; Delfi M; Hashemi F; Zabolian A; Saleki H; Bagherian M; Azami N; Farahani MV; Sharifzadeh SO; Hamzehlou S; Hushmandi K; Makvandi P; Zarrabi A; Hamblin MR; Varma RS
Carbohydr Polym; 2021 May; 260():117809. PubMed ID: 33712155
[TBL] [Abstract][Full Text] [Related]
32. Roles of Chitosan in Green Synthesis of Metal Nanoparticles for Biomedical Applications.
Phan TTV; Phan DT; Cao XT; Huynh TC; Oh J
Nanomaterials (Basel); 2021 Jan; 11(2):. PubMed ID: 33494225
[TBL] [Abstract][Full Text] [Related]
33. Size-Tunable Strategies for a Tumor Targeted Drug Delivery System.
Yu W; Liu R; Zhou Y; Gao H
ACS Cent Sci; 2020 Feb; 6(2):100-116. PubMed ID: 32123729
[TBL] [Abstract][Full Text] [Related]
34. In vitro-in vivo evaluation of chitosan-PLGA nanoparticles for potentiated gastric retention and anti-ulcer activity of diosmin.
Abd El Hady WE; Mohamed EA; Soliman OAE; El-Sabbagh HM
Int J Nanomedicine; 2019; 14():7191-7213. PubMed ID: 31564873
[TBL] [Abstract][Full Text] [Related]
35. Understanding Apoptosis and Apoptotic Pathways Targeted Cancer Therapeutics.
Jan R; Chaudhry GE
Adv Pharm Bull; 2019 Jun; 9(2):205-218. PubMed ID: 31380246
[TBL] [Abstract][Full Text] [Related]
36. Molecular and histological correlations in liver cancer.
Calderaro J; Ziol M; Paradis V; Zucman-Rossi J
J Hepatol; 2019 Sep; 71(3):616-630. PubMed ID: 31195064
[TBL] [Abstract][Full Text] [Related]
37. FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation.
Norsworthy KJ; Luo L; Hsu V; Gudi R; Dorff SE; Przepiorka D; Deisseroth A; Shen YL; Sheth CM; Charlab R; Williams GM; Goldberg KB; Farrell AT; Pazdur R
Clin Cancer Res; 2019 Jun; 25(11):3205-3209. PubMed ID: 30692099
[TBL] [Abstract][Full Text] [Related]
38. Ivosidenib: First Global Approval.
Dhillon S
Drugs; 2018 Sep; 78(14):1509-1516. PubMed ID: 30209701
[TBL] [Abstract][Full Text] [Related]
39. Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma.
Tang X; Chen L; Li A; Cai S; Zhang Y; Liu X; Jiang Z; Liu X; Liang Y; Ma D
Drug Deliv; 2018 Nov; 25(1):1484-1494. PubMed ID: 29916268
[TBL] [Abstract][Full Text] [Related]
40. Crystal structure-based discovery of a novel synthesized PARP1 inhibitor (OL-1) with apoptosis-inducing mechanisms in triple-negative breast cancer.
Fu L; Wang S; Wang X; Wang P; Zheng Y; Yao D; Guo M; Zhang L; Ouyang L
Sci Rep; 2016 Dec; 6(1):3. PubMed ID: 28442756
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
